The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil

Página do item simplificado
dc.citation.issue2
dc.citation.volume36
dc.contributor.authorPires de Lemos, Livia Lovato
dc.contributor.authorGuerra Junior, Augusto Afonso
dc.contributor.authorSantos, Marisa
dc.contributor.authorMagliano, Carlos
dc.contributor.authorDiniz, Isabela
dc.contributor.authorSouza, Kathiaja [UNIFESP]
dc.contributor.authorPereira, Ramon Goncalves
dc.contributor.authorAlvares, Juliana
dc.contributor.authorGodman, Brian
dc.contributor.authorBennie, Marion
dc.contributor.authorZimmermann, Ivan Ricardo
dc.contributor.authorCanuto dos Santos, Vania Crisitna
dc.contributor.authorPretramale, Clarice Alegre
dc.contributor.authorAcurcio, Francisco de Assis
dc.coverageNorthcote
dc.date.accessioned2020-07-08T13:09:47Z
dc.date.available2020-07-08T13:09:47Z
dc.date.issued2018
dc.description.abstractIn Brazil, inclusion and exclusion of health technologies within the Unified Health System (SUS) is the responsibility of the National Committee for Health Technology Incorporation (CONITEC). A recent Cochrane systematic review demonstrated that intramuscular interferon beta 1a (IFN-beta-1a-IM) was inferior to the other beta interferons (IFN-beta s) for multiple sclerosis (MS). As a result, CONITEC commissioned an analysis to review possible disinvestment within SUS. The objective of this paper is to describe the disinvestment process for IFN-beta-1a-IM in Brazil. The first assessment comprised a literature review and mixed treatment comparison meta-analysis. The outcome of interest was the proportion of relapse-free patients in 2 years. This analysis confirmed the inferiority of IFN-beta-1a-IM. Following this, CONITEC recommended disinvestment, with the decision sent for public consultation. More than 3000 contributions were made on CONITEC's webpage, most of them against the preliminary decision. As a result, CONITEC commissioned a study to assess the effectiveness of IFN-beta-1a-IM among Brazilian patients in routine clinical care. The second assessment involved an 11-year follow-up of a non-concurrent cohort of 12,154 MS patients developed by deterministic-probabilistic linkage of SUS administrative databases. The real-world assessment further demonstrated that IFN-beta-1a-IM users had a statistically higher risk of treatment failure, defined as treatment switching or relapse treatment or death, with the assessment showing that IFN-beta-1a-IM was inferior to the other IFN-beta s and to glatiramer acetate in both direct and indirect analysis. In the drug ranking with 40,000 simulations, IFN-beta-1a-IM was the worst option, with a success rate of only 152/40,000. Following this, CONITEC decided to exclude the intramuscular presentation of IFN-beta from the current MS treatment guidelines, giving patients who are currently on this treatment the option of continuing until treatment failure. In conclusion, we believe this is the first example of this new disinvestment process in action, providing an exemplar for other treatments in Brazil as well as other countries.en
dc.description.affiliationUniv Fed Minas Gerais, Fac Farm, SUS Collaborating Ctr Technol Assessment & Excell, Sala 1042,Ave Presidente Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil
dc.description.affiliationUniv Fed Minas Gerais, Fac Med, Programa Posgrad Saude Publ, Sala 533,Ave Porf Alfredo Balena 190,Campus Saude, BR-30130100 Belo Horizonte, MG, Brazil
dc.description.affiliationUniv Fed Minas Gerais, Fac Farm, Programa Posgrad Medicamentos & Assistencia Farma, Sala 1023,Ave Presidente Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil
dc.description.affiliationInst Nacl Cardiol, Nucleo Avaliacao Tecnol Saude, R Laranjeiras 374, BR-22240006 Rio De Janeiro, RJ, Brazil
dc.description.affiliationMinist Saude, Dept Gestao & Inc Tecnol Saude, Secretaria Ciencia Tecnol & Insumos Estrateg, Esplanada Minist Bloco G, BR-70058900 Brasilia, DF, Brazil
dc.description.affiliationUniv Fed Sao Paulo, Programa Posgrad Saude Baseada Evidencias, Rua Botucatu 740,3 Andar, BR-04023900 Sao Paulo, SP, Brazil
dc.description.affiliationKarolinska Inst, Karolinska Univ Hosp Huddinge, Div Clin Pharmacol, S-14186 Stockholm, Sweden
dc.description.affiliationUniv Strathclyde, Strathclyde Inst Pharm & Biomed Sci, 161 Cathedral St, Glasgow G4 0RE, Lanark, Scotland
dc.description.affiliationUniv Liverpool, Sch Management, Ctr Hlth Econ, Liverpool, Merseyside, England
dc.description.affiliationUnifespUniv Fed Sao Paulo, Programa Posgrad Saude Baseada Evidencias, Rua Botucatu 740,3 Andar, BR-04023900 Sao Paulo, SP, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipMinistry of Health of Brazil
dc.description.sponsorshipIDMinistry of Health of Brazil: TED 78/2015, BR/LOA 1500033.001
dc.format.extent161-173
dc.identifierhttp://dx.doi.org/10.1007/s40273-017-0579-0
dc.identifier.citationPharmacoeconomics. Northcote, v. 36, n. 2, p. 161-173, 2018.
dc.identifier.doi10.1007/s40273-017-0579-0
dc.identifier.fileWOS000424691300004.pdf
dc.identifier.issn1170-7690
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/54206
dc.identifier.wosWOS:000424691300004
dc.language.isoeng
dc.publisherAdis Int Ltd
dc.relation.ispartofPharmacoeconomics
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleThe Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazilen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
WOS000424691300004.pdf
Tamanho:
1.06 MB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
EPM - Artigos